Literature DB >> 36063165

[Lupus nephritis].

Johanna Mucke1, Matthias Schneider2.   

Abstract

Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus. Urine analysis is suitable for screening and proteinuria or an active sediment with acanthocytes can be indicative for LN. The gold standard for confirming the diagnosis is a kidney biopsy. The type and extent of the histological alterations are decisive for treatment. The LN is histologically classified into six classes, whereby classes III, IV and V in particular require immunosuppressive treatment. The treatment of LN consists of the administration of hydroxychloroquine, angiotensin-converting enzyme (ACE) inhibitors for nephroprotection and further antihypertensive drugs in cases of arterial hypertension. For prognostically unfavorable forms of LN an immunosuppressive treatment is necessary and a variety of substances are available for this. The immunosuppressive treatment is spread over several years, whereby intensive treatment can mostly be de-escalated after 3-6 months. Despite good treatment options the risk of recurrence and also for chronic renal damage with terminal renal failure is elevated and continuous monitoring is absolutely necessary.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Connective tissue disease; Glomerulonephritis; Immunosuppressive treatment; Nephrology; Systemic lupus erythematosus

Year:  2022        PMID: 36063165     DOI: 10.1007/s00393-022-01250-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.530


  1 in total

1.  Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER).

Authors:  Vicenç Torrente-Segarra; Tarek Carlos Salman Monte; Iñigo Rúa-Figueroa; Fernando Sánchez-Alonso; Francisco Javier López-Longo; María Galindo-Izquierdo; Jaime Calvo-Alén; Alejandro Olivé-Marqués; Jesús Ibañez-Ruán; Loreto Horcada; Ana Sánchez-Atrio; Carlos Montilla; Rafael Benito Melero González; Elvira Díez-Álvarez; Victor Martinez-Taboada; José Luis Andreu; Olaia Fernández-Berrizbeitia; José Ángel Hernández-Beriain; Marian Gantes; Blanca Hernández-Cruz; Ángela Pecondón-Español; Carlos Marras; Gema Bonilla; José M Pego-Reigosa
Journal:  Clin Exp Rheumatol       Date:  2017-06-12       Impact factor: 4.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.